Spots Global Cancer Trial Database for The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Official Title: The Durability of Protection Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Women Aged 18 to 45 Years

Study ID: NCT04969445

Conditions

Cervical Intraepithelial Neoplasia

Cervical Cancer

Vaginal Intraepithelial Neoplasia

Vulvar Intraepithelial Neoplasia

Persistent Infection

Interventions

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)

Study Description

Brief Summary: The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.

Detailed Description: This is a follow-up study that is based on phase III clinical study of a recombinant human papillomavirus 16/18 bivalent vaccine in females aged 18-45 years (Unique Protocol ID: HPV-PRO-003, Identifiers: NCT01735006). The investigators will recruit people who have participated in phase III clinical study on Hebei Province before and to evaluate the durability of protection of the bivalent HPV vaccine on 90m and 114m after dose 1.